James M Rae Selected Research

Cytochrome P-450 CYP2D6 (CYP2D6)

1/2017	Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
5/2015	Re: Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.
9/2013	Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.
7/2013	CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer.
3/2012	CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
3/2012	CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
1/2012	Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes.
4/2010	Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients.
12/2009	CYP2D6 testing for breast cancer patients: is there more to the story?
10/2009	Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James M Rae Research Topics

Disease

78	Breast Neoplasms (Breast Cancer) 10/2022 - 12/2003
47	Neoplasms (Cancer) 03/2022 - 08/2003
5	Circulating Neoplastic Cells 01/2021 - 07/2008
5	Neoplasm Metastasis (Metastasis) 01/2018 - 01/2004
5	Prostatic Neoplasms (Prostate Cancer) 01/2016 - 02/2005
4	Hot Flashes 10/2009 - 12/2003
3	Melanoma (Melanoma, Malignant) 12/2021 - 01/2004
2	Pain (Aches) 10/2022 - 02/2012
2	Triple Negative Breast Neoplasms 01/2022 - 01/2020
2	Peripheral Nervous System Diseases (PNS Diseases) 01/2020 - 01/2020
1	Bone Diseases (Bone Disease) 01/2022
1	Osteonecrosis (Kienbock's Disease) 01/2022
1	Retinoblastoma (Glioblastoma, Retinal) 01/2022
1	Charcot-Marie-Tooth Disease (Peroneal Muscular Atrophy) 01/2020
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2019
1	Disease Progression 01/2019
1	Cystic Fibrosis (Mucoviscidosis) 01/2019
1	Cardiovascular Diseases (Cardiovascular Disease) 03/2016
1	Cardiotoxicity 02/2016
1	Syndrome (Syndromes) 01/2016

Drug/Important Bio-Agent (IBA)

28	Hormones (Hormone)IBA 10/2022 - 02/2005
22	Estrogen ReceptorsIBA 04/2022 - 01/2008
22	Estrogens (Estrogen)FDA Link 03/2022 - 07/2005
20	Tamoxifen FDA LinkGeneric 03/2022 - 12/2003
18	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 01/2017 - 12/2003
16	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 01/2004
14	Letrozole (Femara)FDA LinkGeneric 10/2022 - 03/2012
13	Aromatase InhibitorsIBA 10/2022 - 05/2009
11	exemestane (Aromasin)FDA Link 10/2022 - 04/2013
8	Pharmaceutical PreparationsIBA 01/2018 - 08/2003
7	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2003
7	Estrogen Receptor alphaIBA 01/2019 - 07/2005
7	ParaffinIBA 01/2016 - 08/2003
6	Fulvestrant (Faslodex)FDA Link 03/2022 - 01/2016
6	Proteins (Proteins, Gene)FDA Link 01/2016 - 02/2005
6	EnzymesIBA 11/2010 - 08/2003
5	AndrogensIBA 01/2022 - 06/2006
4	Estradiol (Delestrogen)FDA LinkGeneric 03/2022 - 01/2008
4	Anastrozole (Arimidex)FDA LinkGeneric 10/2017 - 03/2012
4	4-hydroxy-N-desmethyltamoxifenIBA 01/2016 - 12/2005
4	Formaldehyde (Formol)FDA Link 01/2016 - 09/2004
4	Progesterone Receptors (Progesterone Receptor)IBA 01/2016 - 01/2006
4	Messenger RNA (mRNA)IBA 11/2014 - 01/2006
3	Cytochrome P-450 CYP3AIBA 01/2019 - 01/2005
3	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019 - 03/2007
3	SteroidsIBA 01/2019 - 05/2009
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019 - 11/2010
2	Androgen Receptors (Androgen Receptor)IBA 01/2022 - 01/2020
2	Immune Checkpoint InhibitorsIBA 12/2021 - 01/2021
2	Biological ProductsIBA 01/2021 - 01/2008
2	LigandsIBA 04/2020 - 01/2020
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2020 - 01/2020
2	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2019 - 04/2006
2	Phosphotransferases (Kinase)IBA 02/2017 - 04/2006
2	Small Interfering RNA (siRNA)IBA 02/2017 - 03/2007
2	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 01/2017 - 12/2005
2	Estrone FDA Link 01/2017 - 02/2012
2	estrone sulfate (Evex)FDA Link 01/2017 - 02/2012
2	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 01/2005 - 12/2003
1	taxaneIBA 10/2022
1	AZD9496IBA 03/2022
1	Zoledronic Acid (Zometa)FDA Link 01/2022
1	Bevacizumab (Avastin)FDA Link 01/2022
1	Pamidronate (Aredia)FDA LinkGeneric 01/2022
1	Diphosphonates (Bisphosphonates)IBA 01/2022
1	Retinoblastoma ProteinIBA 01/2022
1	thymidine kinase 1IBA 11/2021
1	Monoclonal AntibodiesIBA 01/2021
1	B7-H1 AntigenIBA 01/2021
1	PhycoerythrinIBA 01/2021
1	palbociclibIBA 12/2020
1	Cyclin-Dependent Kinase 4IBA 12/2020
1	seviteronelIBA 01/2020
1	Androgen Receptor AntagonistsIBA 01/2020
1	LyasesIBA 01/2020
1	Steroid 17-alpha-Hydroxylase (17 alpha Hydroxylase)IBA 01/2020
1	Methotrexate (Mexate)FDA LinkGeneric 01/2019
1	Cytochrome P-450 CYP3A InhibitorsIBA 01/2019
1	Fluorouracil (Carac)FDA LinkGeneric 01/2019
1	pazopanib FDA Link 01/2019
1	butylparabenIBA 01/2018
1	4-hydroxybenzoic acid (p-hydroxybenzoate)IBA 01/2018
1	Cyclin CIBA 02/2017
1	IceIBA 12/2016
1	Edetic Acid (EDTA)FDA Link 12/2016
1	LipidsIBA 03/2016
1	AnthracyclinesIBA 02/2016
1	Vitamin E FDA LinkGeneric 01/2016
1	Progesterone FDA LinkGeneric 01/2016
1	SeleniumIBA 01/2016
1	abirateroneIBA 01/2016
1	Long Noncoding RNAIBA 01/2016
1	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2016

Therapy/Procedure

37	Therapeutics 03/2022 - 08/2003
7	Drug Therapy (Chemotherapy) 01/2020 - 03/2007
4	Radiotherapy 01/2022 - 02/2005
3	Adjuvant Chemotherapy 01/2019 - 10/2009
1	Time-to-Treatment 10/2022
1	Precision Medicine 01/2018
1	Castration 01/2016